CING Cingulate Inc

Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and Chief Executive Officer, Shane J. Schaffer, PharmD, will present a company overview at the Diamond Equity Research 2022 Virtual Emerging Growth Invitational on Thursday, June 23, 2022 at 1:40 PM EST. Following the presentation, Dr. Schaffer will take questions from participants.

Investors can register for the conference at: Diamond Equity – Conference Registration.  

A live webcast of the presentation may be accessed at: Diamond Equity – Cingulate Live Presentation. A replay will be available on the investor section of Cingulate’s website at Cingulate Events & Presentations for 90 days.

About Cingulate®Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, such as anxiety disorders.

Cingulate is headquartered in Kansas City, KS. For more information visit Cingulate.com

Investor Relations                                                            Thomas Dalton Head of Investor & Public Relations (913) 942-2301TDalton@cingulate.com                                                

Matt KrepsDarrow Associates(214) 597-8200mkreps@darrowir.com

Media RelationsMelyssa WeibleElixir Health Public Relations(201) 723-5805mweible@elixirhealthpr.com